Compare FIVN & XNCR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | FIVN | XNCR |
|---|---|---|
| Founded | 2001 | 1997 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | EDP Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.2B | 2.0B |
| IPO Year | 2014 | 2013 |
| Metric | FIVN | XNCR |
|---|---|---|
| Price | $32.90 | $27.59 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 18 | 9 |
| Target Price | ★ $26.06 | $22.33 |
| AVG Volume (30 Days) | ★ 3.4M | 1.1M |
| Earning Date | 04-30-2026 | 05-08-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 364.71 | 65.36 |
| EPS | ★ 0.25 | N/A |
| Revenue | ★ $1,149,088,000.00 | $125,576,000.00 |
| Revenue This Year | $11.39 | N/A |
| Revenue Next Year | $10.00 | $4.80 |
| P/E Ratio | $129.20 | ★ N/A |
| Revenue Growth | 10.28 | ★ 13.65 |
| 52 Week Low | $13.29 | $7.72 |
| 52 Week High | $34.58 | $27.70 |
| Indicator | FIVN | XNCR |
|---|---|---|
| Relative Strength Index (RSI) | 61.21 | 79.96 |
| Support Level | $17.59 | $11.05 |
| Resistance Level | $34.58 | N/A |
| Average True Range (ATR) | 2.01 | 1.32 |
| MACD | -0.10 | 0.48 |
| Stochastic Oscillator | 73.51 | 94.94 |
Five9 offers cloud-native contact center software enabling digital customer service, sales, and marketing engagement. The company's Intelligent CX platform combines core telephony functionality, omnichannel engagement, and modules into a cloud contact-center-as-a-service, or CCaaS, platform. Five9's modules include digital self-service, agent assist technology, workflow automation, and optimization solutions, as well as artificial intelligence-driven automation solutions that optimize customer service efficiency and manage interaction quality and agent performance.
Xencor Inc is a clinical-stage biopharmaceutical company focused on discovering and developing engineered antibody therapeutics to treat patients with cancer and autoimmune diseases. The company uses its XmAb technology platform to create antibody product candidates. Its pipeline includes XmAb819, XmAb541, XmAb808, XmAb942, Plamotamab and XmAb657. The group earns its revenue from collaboration agreements and licensing agreements and operates as a single reportable segment focused on discovering and developing engineered antibody therapeutics to treat patients with cancer and autoimmune diseases who have unmet medical needs.